Literature DB >> 33580938

What is new in dermatotherapy?

Anupam Das1, Anand Toshniwal2, Bhushan Madke3.   

Abstract

Year:  2021        PMID： 33580938     DOI： 10.25259/IJDVL_342_20

Source DB:  PubMed          Journal:  Indian J Dermatol Venereol Leprol        ISSN： 0378-6323            Impact factor:   2.545


× No keyword cloud information.
  48 in total

1.  Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate-to-severe plaque psoriasis: results from a randomized phase II study.

Authors:  K Reich; P Rich; C Maari; R Bissonnette; C Leonardi; A Menter; A Igarashi; P Klekotka; D Patel; J Li; J Tuttle; M Morgan-Cox; E Edson-Heredia; S Friedrich; K Papp
Journal:  Br J Dermatol       Date:  2019-04-17       Impact factor: 9.302

2.  Beta-blockers for treatment of autoimmune blistering dermatosis.

Authors:  A Abdelmaksoud; M Vestita
Journal:  J Eur Acad Dermatol Venereol       Date:  2018-05-28       Impact factor: 6.166

3.  Dual-targeted therapy with apremilast and vedolizumab in pyoderma gangrenosum associated with Crohn's disease.

Authors:  Marta Vernero; Davide Giuseppe Ribaldone; Caterina Cariti; Simone Ribero; Sara Susca; Marco Astegiano; Paolo Dapavo
Journal:  J Dermatol       Date:  2020-04-29       Impact factor: 4.005

4.  Efficacy and safety of apremilast for Behçet's syndrome: a real-life single-centre Italian experience.

Authors:  Giacomo De Luca; Adriana Cariddi; Corrado Campochiaro; Daniele Vanni; Nicola Boffini; Alessandro Tomelleri; Giulio Cavalli; Lorenzo Dagna
Journal:  Rheumatology (Oxford)       Date:  2020-01-01       Impact factor: 7.580

5.  Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.

Authors:  Mark Lebwohl; Bruce Strober; Alan Menter; Kenneth Gordon; Jolanta Weglowska; Lluis Puig; Kim Papp; Lynda Spelman; Darryl Toth; Francisco Kerdel; April W Armstrong; Georg Stingl; Alexa B Kimball; Herve Bachelez; Jashin J Wu; Jeffrey Crowley; Richard G Langley; Tomasz Blicharski; Carle Paul; Jean-Philippe Lacour; Stephen Tyring; Leon Kircik; Sergio Chimenti; Kristina Callis Duffin; Jerry Bagel; John Koo; Gary Aras; Joanne Li; Wenjie Song; Cassandra E Milmont; Yifei Shi; Ngozi Erondu; Paul Klekotka; Brian Kotzin; Ajay Nirula
Journal:  N Engl J Med       Date:  2015-10       Impact factor: 91.245

6.  A Phase 2 Randomized Trial of Apremilast in Patients with Atopic Dermatitis.

Authors:  Eric L Simpson; Shinichi Imafuku; Yves Poulin; Benjamin Ungar; Lisa Zhou; Kunal Malik; Huei-Chi Wen; Hui Xu; Yeriel D Estrada; Xiangyu Peng; Mindy Chen; Nilam Shah; Mayte Suarez-Farinas; Ana B Pavel; Kristine Nograles; Emma Guttman-Yassky
Journal:  J Invest Dermatol       Date:  2018-12-05       Impact factor: 8.551

7.  Efficacy and safety of ixekizumab in patients with plaque psoriasis across different degrees of disease severity: results from UNCOVER-2 and UNCOVER-3.

Authors:  Lajos Kemény; Lovisa Berggren; Martin Dossenbach; Yves Dutronc; Carle Paul
Journal:  J Dermatolog Treat       Date:  2018-06-12       Impact factor: 3.359

8.  Apremilast for moderate hidradenitis suppurativa: Results of a randomized controlled trial.

Authors:  Allard R J V Vossen; Martijn B A van Doorn; Hessel H van der Zee; Errol P Prens
Journal:  J Am Acad Dermatol       Date:  2018-07-03       Impact factor: 11.527

9.  Novel use of apremilast for adjunctive treatment of recalcitrant pyoderma gangrenosum.

Authors:  Mary E Laird; Lana X Tong; Kristen I Lo Sicco; Randie H Kim; Shane A Meehan; Andrew G Franks
Journal:  JAAD Case Rep       Date:  2017-04-14

10.  Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial.

Authors:  Eric L Simpson; Amy S Paller; Elaine C Siegfried; Mark Boguniewicz; Lawrence Sher; Melinda J Gooderham; Lisa A Beck; Emma Guttman-Yassky; David Pariser; Andrew Blauvelt; Jamie Weisman; Benjamin Lockshin; Thomas Hultsch; Qin Zhang; Mohamed A Kamal; John D Davis; Bolanle Akinlade; Heribert Staudinger; Jennifer D Hamilton; Neil M H Graham; Gianluca Pirozzi; Abhijit Gadkari; Laurent Eckert; Neil Stahl; George D Yancopoulos; Marcella Ruddy; Ashish Bansal
Journal:  JAMA Dermatol       Date:  2020-01-01       Impact factor: 10.282
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.